Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerZongbi Yi, Fei Ma, Lianpeng Chang et al.|npj Breast Cancer|2020Cited by 74
Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)Chunxiao Li, Xiumin Wang|Frontiers in Pharmacology|2024Cited by 57
Molecular landscape of <scp><i>TP53</i></scp> mutations in breast cancer and their utility for predicting the response to <scp>HER</scp>‐targeted therapy in <scp>HER2</scp> amplification‐positive and <scp>HER2</scp> mutation‐positive amplification‐negative patientsBinliang Liu, Yixin Zeng, Zongbi Yi et al.|Cancer Medicine|2022Cited by 27